.jpg)
In a report issued on December 17, James Jang from Univest Securities maintained a Buy rating on Alzamend Neuro (ALZN – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $2.45, close to its 52-week low of $1.87.
Jang has an average return of 4.4% when recommending Alzamend Neuro.
According to TipRanks.com, Jang is ranked #7554 out of 7739 analysts.
Currently, the analyst consensus on Alzamend Neuro is a Moderate Buy with an average price target of $11.50.
See the top stocks recommended by analysts >>
Based on Alzamend Neuro’s latest earnings release for the quarter ending July 31, the company reported a quarterly GAAP net loss of $2.32 million. In comparison, last year the company had a GAAP net loss of $1.26 million.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALZN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline of product candidates consist of two novel therapeutic drug candidates namely AL001 a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, and; AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s.
Read More on ALZN: